Scientists from the National Institutes of Health (NIH) have identified an antibody from an HIV-infected person that potently neutralized 98% of HIV isolates tested, including 16 of 20 strains resistant to other antibodies of the same class.
The remarkable breadth and potency of this antibody, named N6, make it an attractive candidate for further development to potentially treat or prevent HIV infection, say the researchers.
HIV Virus Now in the List of US Department of Health and Human Services 14th Report on Carcinogens
Five viruses and two chemicals have been added to the list of carcinogens released by the U.S. Department of Health and Human Services.
Advertisement
‘The ability of the antibody N6 to neutralize nearly all HIV strains would be advantageous for both prevention and treatment strategies.’
Tweet it Now
The scientists, led by Mark Connors, M.D., of NIH's National Institute of Allergy and Infectious Diseases (NIAID), also tracked the evolution of N6 over time to understand how it developed the ability to potently neutralize nearly all HIV strains.
This information will help inform the design of vaccines to elicit such broadly neutralizing antibodies.
Identifying broadly neutralizing antibodies against HIV has been difficult because the virus rapidly changes its surface proteins to evade recognition by the immune system.
![First Month is Key Time to Tackle Drug-Related HIV Spread]( "First Month is Key Time to Tackle Drug-Related HIV Spread")
The first month after infection is the key period to control the spread of the virus in drug-using populations.
In 2010, scientists at NIAID's Vaccine Research Center (VRC) discovered an antibody called VRC01 that can stop up to 90% of HIV strains from infecting human cells.
Like VRC01, N6 blocks infection by binding to a part of the HIV envelope called the CD4 binding site, preventing the virus from attaching itself to immune cells.
Findings from the current study showed that N6 evolved a unique mode of binding that depends less on a variable area of the HIV envelope known as the V5 region and focuses more on conserved regions, which change relatively little among HIV strains.
This allows N6 to tolerate changes in the HIV envelope, including the attachment of sugars in the V5 region, a major mechanism by which HIV develops resistance to other VRC01-class antibodies.
The new findings suggest that N6 could pose advantages over VRC01, which currently is being assessed as intravenous infusions in clinical trials to see if it can safely prevent HIV infection in humans.
Due to its potency, N6 may offer stronger and more durable prevention and treatment benefits, and researchers may be able to administer it subcutaneously (into the fat under the skin) rather than intravenously.
In addition, its ability to neutralize nearly all HIV strains would be advantageous for both prevention and treatment strategies.
Source: Medindia
Identifying broadly neutralizing antibodies against HIV has been difficult because the virus rapidly changes its surface proteins to evade recognition by the immune system.
First Month is Key Time to Tackle Drug-Related HIV Spread
The first month after infection is the key period to control the spread of the virus in drug-using populations.
Advertisement
In 2010, scientists at NIAID's Vaccine Research Center (VRC) discovered an antibody called VRC01 that can stop up to 90% of HIV strains from infecting human cells.
Like VRC01, N6 blocks infection by binding to a part of the HIV envelope called the CD4 binding site, preventing the virus from attaching itself to immune cells.
Findings from the current study showed that N6 evolved a unique mode of binding that depends less on a variable area of the HIV envelope known as the V5 region and focuses more on conserved regions, which change relatively little among HIV strains.
This allows N6 to tolerate changes in the HIV envelope, including the attachment of sugars in the V5 region, a major mechanism by which HIV develops resistance to other VRC01-class antibodies.
The new findings suggest that N6 could pose advantages over VRC01, which currently is being assessed as intravenous infusions in clinical trials to see if it can safely prevent HIV infection in humans.
Due to its potency, N6 may offer stronger and more durable prevention and treatment benefits, and researchers may be able to administer it subcutaneously (into the fat under the skin) rather than intravenously.
In addition, its ability to neutralize nearly all HIV strains would be advantageous for both prevention and treatment strategies.
Source: Medindia
New Device Helps Diagnose HIV in 30 Minutes
New technology allows HIV patients to monitor their treatment. The device is not only very accurate but can produce a result in under 30 minutes.
Advertisement
 Quiz on HIV SymptomsDo you know that there are symptoms for each stage of HIV/AIDS? Learn more from our HIV Symptom Quiz but here's a disclaimer - never go by symptoms alone. Symptoms only indicate the progression of the disease, while only a medical test can confirm it. | Advertisement
|
Advertisement
Recommended Reading
Latest AIDS/HIV News
In India, annual HIV infections and AIDS-related deaths continue to drop. Between 2010 and 2021, new HIV infections dropped by 46%.
Globally, all countries have promised to end AIDS by 2030, for which it is essential to safeguard individuals living with HIV to complete HIV care services.
How can you prevent HIV while breastfeeding? A monthly vaginal ring containing the antiretroviral drug dapivirine safely prevents HIV infection while breastfeeding.
Union Minister of State for Health Bharti Pravin Pawar had said that the government is providing free lifelong antiretroviral (ARV) medicines for people living with HIV.
Dr. Korosi said the goal to end AIDS by 2030 is badly off track, as inequalities, discrimination, and disregard for human rights are hampering our progress.